| pubmed-article:8301043 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8301043 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8301043 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8301043 | lifeskim:mentions | umls-concept:C0520463 | lld:lifeskim |
| pubmed-article:8301043 | lifeskim:mentions | umls-concept:C0004358 | lld:lifeskim |
| pubmed-article:8301043 | lifeskim:mentions | umls-concept:C0052495 | lld:lifeskim |
| pubmed-article:8301043 | lifeskim:mentions | umls-concept:C0443146 | lld:lifeskim |
| pubmed-article:8301043 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8301043 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8301043 | pubmed:dateCreated | 1994-3-8 | lld:pubmed |
| pubmed-article:8301043 | pubmed:abstractText | The hepatic asialoglycoprotein receptor (ASGPR) was recently identified as a target antigen for both humoral and cellular immune response in inflammatory liver diseases. Thereby anti-ASGPR autoantibodies directed against human substrate were closely associated with autoimmune chronic active hepatitis. The present study compares the occurrence, titer and immunoglobulin classification of anti-human(h-)-ASGPR antibodies in 23 patients with newly diagnosed autoimmune chronic hepatitis before and after initiation of immunosuppressive therapy to 22 patients with autoimmune hepatitis in remission. Additionally, 1-year follow-up examinations of 42 patients with HBsAg-positive chronic hepatitis and of 32 patients with chronic hepatitis C receiving recombinant interferon-alpha were included. Nineteen of 23 patients with newly diagnosed and 9/22 with autoimmune hepatitis in remission, 5/42 with untreated chronic hepatitis B and 5/32 patients with chronic hepatitis C exhibited anti-h-ASGPR at the beginning of the study. In autoimmune hepatitis anti-h-ASGPR were found in higher titers (median > 1:1000) than in viral hepatitis (maximum 1:400). After initiation of immunosuppressive therapy in autoimmune hepatitis anti-h-ASGPR decreased sharply. Eight of 19 patients eliminated anti-h-ASGPR within 18 months in contrast to 11 patients with persistent anti-h-ASGPR titer over 18 months and longer. Anti-h-ASGPR with maximum titer of 1:600 were detected in 5 patients with chronic hepatitis B (transiently in 4/5 patients) and in 2 patients with chronic hepatitis C during interferon-alpha. Anti-h-ASGPR were from immunoglobulin classes IgG and IgM in cases with untreated autoimmune hepatitis and chronic hepatitis B and C exhibiting mainly IgG2-subclass in autoimmune and IgG4 in viral hepatitis.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:8301043 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8301043 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8301043 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8301043 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8301043 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8301043 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8301043 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8301043 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8301043 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8301043 | pubmed:issn | 0168-8278 | lld:pubmed |
| pubmed-article:8301043 | pubmed:author | pubmed-author:RotthauweH... | lld:pubmed |
| pubmed-article:8301043 | pubmed:author | pubmed-author:Meyer zum... | lld:pubmed |
| pubmed-article:8301043 | pubmed:author | pubmed-author:RossolSS | lld:pubmed |
| pubmed-article:8301043 | pubmed:author | pubmed-author:GerkenGG | lld:pubmed |
| pubmed-article:8301043 | pubmed:author | pubmed-author:PorallaTT | lld:pubmed |
| pubmed-article:8301043 | pubmed:author | pubmed-author:TreichelUU | lld:pubmed |
| pubmed-article:8301043 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8301043 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:8301043 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8301043 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8301043 | pubmed:pagination | 55-63 | lld:pubmed |
| pubmed-article:8301043 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:meshHeading | pubmed-meshheading:8301043-... | lld:pubmed |
| pubmed-article:8301043 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8301043 | pubmed:articleTitle | Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. | lld:pubmed |
| pubmed-article:8301043 | pubmed:affiliation | 1st Department of Internal Medicine, University of Mainz, Germany. | lld:pubmed |
| pubmed-article:8301043 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8301043 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8301043 | lld:pubmed |
